瑞加诺生负荷心肌灌注磁共振:在儿童及年轻成人人群中的初步经验
回顾31例15.8±1.7岁(12-22岁)先天性及获得性心脏病患儿,以400 mcg瑞加诺生行负荷心肌灌注心脏磁共振,静息心率72±14 bpm升至峰值124±17 bpm(升高95±50%,P<0.005),全部图像质量良好或可诊断,3例不可逆灌注缺损、4例可逆灌注缺损,9例导管造影结果高度一致;作者认为瑞加诺生可能是该人群安全可行的药物负荷剂。
要点
- 瑞加诺生400 mcg团注后心率由静息72±14 bpm升至峰值124±17 bpm(升高95±50%,P<0.005)。
- 全部病例图像质量评为良好或可诊断,1例未能完成负荷灌注部分但完成其余心脏磁共振检查。
- 31例中3例不可逆灌注缺损、4例可逆灌注缺损,9例行导管造影者结果高度一致。
核心结论
- 作者认为瑞加诺生可能是用于先天性心脏病和获得性心脏病年长儿科患者心脏磁共振的安全可行药物负荷剂。
- 瑞加诺生团注使用方便且高灌注期延长,使其在儿科应用中具有吸引力。
- 在有限病例中,瑞加诺生负荷灌注与导管造影显示高度一致,作者认为其可能是该人群可行的药物负荷剂。
研究设计与样本
- 回顾性分析本中心初始经验的试点队列,共31例15.8±1.7岁(范围12-22岁)先天性心脏病和获得性心脏病儿科患者。
- 平均体重60±15 kg(范围40-93 kg),所有患者因怀疑缺血行心脏磁共振。
- 药理负荷通过注射400 mcg瑞加诺生诱导,监测心率和血压,并由儿科心脏病专家和放射科医生定性评估心肌灌注和存活心肌图像。
关键影像表现/征象
- 3例患者存在不可逆灌注缺损,4例患者存在可逆灌注缺损。
- 9例患者行心导管造影,结果与灌注成像显示高度一致。
- 全部病例图像质量评为良好或可诊断。
诊断标准与关键数值
- 静息心率为72±14次/分(bpm),瑞加诺生后升至峰值124±17 bpm(升高95±50%,P<0.005)。
- 1例儿童未能完成检查的负荷灌注部分,但完成了心脏磁共振其余部分。
临床应用与阅片要点
- 作者认为瑞加诺生可能是年长儿科先天性心脏病和获得性心脏病患者心脏磁共振的安全可行药物负荷剂。
- 作者认为瑞加诺生团注使用方便且高灌注期延长,使其在儿科应用中具有吸引力。
局限性
- 原文为试点队列的初始经验回顾,病例数有限。
- 作者在结论中称瑞加诺生「可能」安全可行,并使用「可能」为可行的药物负荷剂,且仅在有限病例中与导管造影比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND: Dipyridamole and adenosine are traditional pharmacological stressors for myocardial perfusion. Regadenoson, a selective adenosine A2A agonist, has a lower side effect profile with lower incidence of bronchospasm and bradycardia. There is a growing need for myocardial perfusion assessment within pediatrics. There is no report on the utility of regadenoson as a stress agent in children.
OBJECTIVE: To observe the safety and feasibility of regadenoson as a pharmacologic stressor for perfusion cardiac MR in a pilot cohort of pediatric patients weighing more than 40 kg who have congenital heart disease and pediatric acquired heart disease.
MATERIALS AND METHODS: We reviewed our initial experience with regadenoson stress cardiac MR in 31 pediatric patients 15.8 ± 1.7 years (range 12-22 years) with congenital heart disease and acquired heart disease. Mean patient weight was 60 ± 15 kg (range of 40-93 kg). All patients underwent cardiac MR because of concern for ischemia. The cohort included a heterogeneous group of patients at a pediatric institution with potential risk for ischemia. Subjects' heart rate and blood pressure were monitored and pharmacologic stress was induced by injection of 400 mcg of regadenoson. We evaluated their hemodynamic response and adverse effects using changes in vital signs and onset of symptoms. A pediatric cardiologist and radiologist qualitatively assessed myocardial perfusion and viability images.
RESULTS: One child was unable to complete the stress perfusion portion of the examination, but did complete the remaining portion of the CMR. Resting heart rate was 72 ± 14 beats per minute (bpm) and rose to peak of 124 ± 17 bpm (95 ± 50% increase, P < 0.005) with regadenoson. Image quality was considered good or diagnostic in all cases. Three patients had irreversible perfusion defects. Four patients had reversible perfusion defects. Nine of the patients underwent cardiac catheterization with angiography and the findings showed excellent agreement.
CONCLUSION: Regadenoson might be a safe and feasible pharmacologic stress agent for use in cardiac MR in older pediatric patients with congenital heart disease and acquired heart disease. The ease of use as a bolus and the advantage of a prolonged hyperemia make its use appealing in pediatrics. In a limited number of cases, regadenoson stress perfusion showed excellent agreement with cardiac catheterization. Regadenoson might be a viable pharmacologic stress agent in this population.
引用
- Noel CV, Krishnamurthy R, Moffett B, et al. Myocardial stress perfusion magnetic resonance: initial experience in a pediatric and young adult population using regadenoson. Pediatr Radiol. 2016. PMID: 28035425. doi:10.1007/s00247-016-3762-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。